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rights reserved.© 2011 Elsevier Inc. All rights reserved.Adeno-associated viruses (AAVs) are 4.7-kb single-stranded DNA
viruses that depend on helper viruses such as adenovirus for replica-
tion (Berns, 1996). There are twelve distinct human serotypes with
AAV-6 as a minor variant of AAV-1 (Gao et al., 2004; Rutledge et al.,
1998; Schmidt et al., 2008). AAVs are small viruses that are wide-
spread in human population, but non-pathogenic. Many of the sero-
types have the potential to be developed as transducing vectors for
gene therapy (Halbert et al., 2001; Rutledge et al., 1998) and also as
vaccine vectors for genetic immunization (Carter, 2005; Dudek and
Knipe, 2006; Manning et al., 1997; Xin et al., 2001). In constructs
designed for such therapies, the recombinant AAV (rAAV) is a non-
replicative form in which its replication and capsid genes are replaced
with the foreign genes to be delivered (Carter, 2006a, 2006b). To date,
vectors in trials have been mostly derived from AAV-2. However,
challenges remain with AAV-2 vectors, including varying transduc-
tion efﬁciencies in different cell types, and inefﬁcient in vivo transduc-
tion following prior exposure to AAV (Gao et al., 2005; Halbert et al.,
1997, 1998; Louboutin et al., 2005; Su et al., 2008; Wang et al., 2005;Wu et al., 2006b). Through improved structural biology of AAV (Xie et
al., 2002), it may be possible to engineer the surface of the capsid for
improved vector transduction, perhaps by taking advantage of the di-
versity among naturally occurring AAV serotypes and their distinctive
characteristics.
Vectors based on other serotypes could prove especially useful for
transducing cells that are resistant to AAV-2 infection (Halbert et al.,
2001). The primary receptor for AAV-2 on the cell surface is heparan
sulfate proteoglycan (HSPG) (Summerford and Samulski, 1998), as it
is for AAV-3 (~87% identity) albeit with reduced binding afﬁnity
(Rabinowitz et al., 2002). AAV-1 (which is ~83% identical to AAV-2),
like AAV-4 and AAV-5 (~58% identical to AAV-2), uses sialic acid-
mediated cell attachment and has low afﬁnity for heparin (Wu et
al., 2006a). AAV-6, like AAV-1, uses sialic acid in attachment (Wu et
al., 2006c). However, unlike AAV-1, from which the capsid differs at
a handful of sites, AAV-6 also binds heparin (Wu et al., 2006a).
Diverse serotypes are also being investigated as possible vectors,
due to their potential to evade host immune responses directed
against AAV-2 (Kuck et al., 2007). Infection by wild type AAV results
in the production of neutralizing antibodies. 50–80% of adults have
neutralizing antibodies to AAV, predominantly against the AAV-2 se-
rotype (Blacklow et al., 1968; Parks et al., 1970). Neutralizing anti-
bodies to AAV-2 are the most prevalent in all regions of the world,
followed by antibodies to AAV-1 (Calcedo et al., 2009). The presence
of high-titer neutralizing antibodies is expected to decrease transduc-
tion rates severely upon (repeated) vector treatments for some
modes of administration. Thus additional transduction was not mea-
surable after re-administration of AAV-2 vectors in animal models
11Q. Xie et al. / Virology 420 (2011) 10–19(Halbert et al., 1997). Russell's group has shown that vectors derived
from AAV-3 and AAV-6 differ from AAV-2 vectors not only in host cell
tropism, but serological reactivity, eliciting distinct humoral responses
(Rutledge et al., 1998). Thus, the different AAV serotypes are being in-
vestigated both for their potential to transduce otherwise refractory
cells, and to deliver genes in patients presenting a neutralizing im-
mune response to some of the serotypes.
Many of the relevant viral-host properties are mediated at the
level of the capsid. Structural studies were initiated both to better un-
derstand the basic biology of AAV serotypes and as a resource for the
future development of vectors based on the various serotypes. Here,
we report the crystallographic structure of serotype AAV-6 and its im-
plications for receptor binding, tested by site-directed mutagenesis.
Results and discussion
Crystal structure of AAV-6
Structures were determined at 3 Å resolution from both rhombo-
hedral and orthorhombic crystal forms. The rhombohedral form
with its high quality diffraction data (Rmerge=0.08; Table 1) and
packing-constrained translation function yielded the better results
on independent phase extensions from 8 to 3 Å. The rhombohedral
structure provided an improved starting point for reﬁnement of the
orthorhombic phases, which, after reﬁnement using 60-fold non-
crystallographic symmetry (NCS), yielded an excellent map (Figs. 1
and S1). The structures differ by 0.8 Å RMSD (0.5 Å Cα), which is
less than the cross-validated maximum likelihood estimated coordi-
nate errors of 1.0 Å (Table 1). The structures have similar R/Rfree of
0.273/0.286 (rhombohedral) and 0.251/0.286 (orthorhombic) when
reﬁned at 3.0 Å. Full statistics are provided in Table 1. Unless other-
wise stated, ﬁgures have been prepared using the rhombohedral
structure.
Interpretable density was present for all but 19 of the 534 amino
acids present in each VP3 subunit (Fig. 1). With differential splicing,
AAV expresses three variants of the capsid protein VP1, VP2 and
VP3 which were conﬁrmed by gel chromatography to be present in
the expected 1:1:8 ratio (Johnson, 1984; Xie et al., 2004, 2008). Re-
solved in the crystal structure are the parts of the capsid protein com-
mon to VP1, 2 and 3 and present in all 60 capsid subunits. Likewise,
the genomic DNA does not adhere to the icosahedral symmetry and
is not seen in most virus structures. Even though it is VP3 that is re-
solved, we follow the conventional VP1 numbering with the model
starting at residue 221.
The largest differences (2.8 Å backbone rms) between our two
crystal forms occur at residues 586–590 on the outer surface. The
backbone density for the rhombohedral form is the least ordered ofTable 1
Data collection and structure reﬁnement statistics. Values in parentheses are for the 3.4–3.
Space group R3
Unit-cell parameters (Å, o) a=b=c=252.9, α=β=γ=61.4 (rhombohedral se
Resolution (Å) 100–3.2
Reﬂections observed 83227
Unique reﬂections 78455
Completeness (%) 32 (30)
Rmerge a (%) 0.08 (0.28)
b IN/bσ(I)N 4.3 (1.5)
Rwork b (50–3.2 Å) 0.265 (0.375)
Rfree (50–3.2 Å) 0.288 (0.403) c
RMSD for bond length (Å) 0.002
RMSD bond angles (o) 0.452
ML based coordinate error 0.96
a Rmerge=∑hkl∑i |Ii(hkl)−b I(hkl)N|/∑hkl∑i Ii(hkl), where Ii(hkl) is the ith observatio
b R=∑−Fo−Fc|/∑Fo, where Fo and Fc are the observed and calculated structure facto
c Rfree biaswasminimized by selecting test reﬂections in thin shells, and by excluding neighbor
and test reﬂections that are correlated by the interference function of the non-crystallographic seither structure, suggestive of multiple conformations. There is
some discontinuous density suggesting that the conformation clearly
seen in the orthorhombic form (and other serotypes) is present, but
stronger discontinuous density follows the alternative path modeled
as the predominant conformation for the rhombohedral form. Only
one of the 20 NCS-related subunits forms an inter-particle contact
in this region, so crystal packing is not the cause of the disorder — it
might reﬂect inherent ﬂexibility.
Subsequent to our determination, a structure was reported for an
AAV-6 virus like particle (VLP), lacking genomic DNA and VP1 (Ng et
al., 2010). The fold and overall structure are similar: the Cα RMS
difference between the empty VLP particles and our infectious virions
is 0.7 and 0.5 Å for the rhombohedral and orthorhombic forms
respectively. A recent cryo-EM study of AAV-1 (a minor variant of
AAV-6) at 10 Å resolution reported capsid changes, mostly on the
inner surface, dependent on the DNA content of particles (Gerlach
et al., 2011). However, comparison at 3 Å resolution of our full AAV-6
particles and the empty VLPs, shows no evidence of changes near the
DNA of a magnitude detectable at 10 Å. Differences between the
infectious virion structures and the VLP are most apparent on the viral
surface. Where disorder was noted (previous paragraph) for residues
586–90, the rhombohedral structure differs from the VLP by 2.9 Å (Cα
RMSD), but the orthorhombic and VLP structures are similar (0.4 Å Cα
RMSD). The largest differences are at 453–456, the tip of another
external loop, where density is understandably weaker than average,
but supports similar rhombohedral and orthorhombic conformations
(0.7 Å Cα RMSD) over a different conformation reported for the VLP
(2.9 Å Cα RMSD). Overall, however, the Cα differences of 0.5–0.7
between infectious virions and VLP is less than that expected from the
overall error estimates. That said, all atom RMSDs (whole subunit, side
chains included) between our capsids and the VLP are substantially
larger (3.0 Å) than the difference between our two structures (0.8 Å).
Flipping of pseudo-symmetrical side chains contributes to this, but larger
contributions come from a small number of side chains pointing in
different directions particularly at the sites (above) where the backbone
differs. Differences in side chain conformation also reﬂect technical
challenges that are common at the 3 Å resolution available for the
three structures.
Precautions taken during the structure determination, together with
multiple cross-validations, support the structures reported here: (1) Dif-
fraction data are of high quality for large complexes (Rmerge=0.08 and
0.11; Table 1); (2) Bias from molecular replacement was avoided
through model-independent phase extension from 8 to 3 Å using only
the icosahedral symmetry; (3) Rhombohedral form test andworking re-
ﬂection setswere selected tomaintain their independence in spite of the
icosahedral symmetry (Fabiola et al., 2006), supporting full cross-
validation and checks against over-ﬁtting; (4) The structures of the2 Å resolution shell.
P212121
tting); a=b=258.4, c=613.0 (hexagonal). a=354.8, b=363.9, c=371.9
100–3.2
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326212
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n of a symmetry equivalent of reﬂection hkl.
r amplitudes, respectively.
ing shells of reﬂections from theworking set. The latter reduces cross-talk betweenworking
ymmetry (Fabiola et al., 2006).
Fig. 1. Introduction to the AAV-6 structure. (a) Representative experimental electron density for the orthorhombic crystal form AAV-6 at 3.2 Å is shown near one of the surface
residues of interest, Arg576. Molecular replacement phases, calculated from the rhombohedral form structure (superimposed with thin lines), omitting 20 residues including
Arg576, were improved by 60-fold averaging, and the resulting (2Fo−Fρav, φρav) map is contoured at 1.0 σ with the subsequently reﬁned orthorhombic structure in stick model.
Additional examples are shown in Fig. S1. (b)Comparison of subunit folds: AAV-6-green, AAV-2-blue, AAV-8-pink, AAV-4-yellow, and AAV-3B-magenta. Three of the variable re-
gions (VR) are annotated to highlight where there are signiﬁcant local differences in the conformation of AAV-6 from other serotypes (VR-I and VR-IV) or where there are sequence
insertions in AAV-4 relative to AAV-6 (VR-V). (c) The proximity of functional surface sites discussed in this paper. The side of the spike is positively charged, but with a different
distribution of basic residues than in AAV-2, implying differences in heparin-binding. Regions implicated in the binding of an AAV-2 neutralizing antibody where there are struc-
tural differences between AAV-2 and AAV-6 are close by.
12 Q. Xie et al. / Virology 420 (2011) 10–19two crystal forms of infectious particles were initially determined inde-
pendently to check that reﬁnements converged to the same structure.
Of greatest functional interest are regions where the sequence dif-
fers between the AAV serotypes. They are predominantly surface-
exposed, but the backbone and much of the side-chain structure was
at least partially ordered and fully traceable, even in the initial 3 Å
rhombohedral map, due to the beneﬁcial impact of 20-fold non-
crystallographic averaging. Full density was available for the four sur-
face residues characteristic to AAV-6 (see below) when the rhombohe-
dral structure was used as the starting point for improved phase
reﬁnement for the orthorhombic form. To avoid bias, these four resi-
dues, together with 580–595, were omitted from the phasing model
(which had not been reﬁned against the orthorhombic data). Lack of
perceptible difference between omit and non-omit maps demonstrates
that the 60-fold NCS of the orthorhombic form is sufﬁcient to yield a re-
liable and unbiased map. Orthorhombic density, consistent with both
structures offers a local real-space cross-validation for the residues of
greatest interest: Lys459, Lys493, Lys531 and Arg576 (Figs. 1 and S1).Table 2
Serotype-characteristic positively charged residues in the heparin-binding region. Can-
didate binding site residues were identiﬁed by superimposing difference density from
the AAV-2/heparin cryo-EM reconstruction upon the atomic structures of AAV-2
(O'Donnell et al., 2009), AAV-3B (Lerch et al., 2010) and AAV-6 (here). Residues that
are near the heparin, with unobstructed (through solvent) access are checked (✓),
while those in direct contact are designated by “✓+”. Structurally aligned residues
for non-heparin binding AAV-1, -4, and -8 are shown for comparison. Those in paren-
theses are in regions where lack of local structural homology leaves some alignment
ambiguity. This list is restricted to residues that are characteristic of AAV-6 (/-1) or
AAV-2, with a full list in Table S3.
AAV-6 AAV-2 AAV-3B AAV-1 AAV-4 AAV-8
Lys459✓+ Ser458 Ser459 Lys459 Ala453 Gln461
Lys493✓+ Ser492 Ala493 Lys493 Ala487 Thr495
Lys531✓+ Glu530✓+ Glu531✓+ Glu531 (Ala529) Glu533
Arg576✓+ Gln575✓ Gln576✓+ Arg576 Met574 Glu578
Ser586✓+ Arg585✓+ Ser586✓+ Ser586 Ser584 Gln588
Thr589✓+ Arg588✓+ Thr589✓+ Thr589 Asn587 Thr591Comparison of AAV-6 to other serotypes
Each AAV-6 subunit shares the jelly-roll β-barrel subunit fold of
other parvoviruses (Fig. 1b) (Tsao et al., 1991) and many other viral
capsids (Chapman and Liljas, 2003). The structures of 4 other AAVs
are available for comparison: AAV-2 (Xie et al., 2002; PDB id 1lp3),
AAV-4 (Govindasamy et al., 2006; PDB id 2g8g), AAV-8 (Nam et al.,
2007; PDB id 2qa0) and AAV-3B (Lerch et al., 2010; PDB id 3kic).
At the level of backbone, the structures are similar (Fig. 1b), but
there are local regions where the serotypes differ. These were
highlighted through alignments of the structures starting with con-
served secondary structures, then iterating joint sequence-structure
alignment (Krissinel and Henrick, 2004). There is good overall agree-
ment between AAV-6 and AAV-2, -3B and -8 (0.7bCα RMSDb0.9 Å).
For AAV-4, the RMSD is 1.6 Å. With AAV-4, the greatest differences
are in the nine variable regions (VR I–IX) identiﬁed in comparisons
of AAV-2 and -4 (Table S1) (Agbandje-McKenna and Chapman,
2006; Govindasamy et al., 2006).
When AAV-6 is compared to AAV-2, -3B and -8, two of the nine re-
gions show substantial differences. The ﬁrst is at the tip of the loop
between strands B and C (βBC, also known as VR-I). We can now
see that VR-I is the site of greatest diversity in the serotype structures
(Table S1), each being distinct. VR-I of AAV-6 contains residues 262–
269, corresponding to part of the epitope in AAV-2 (262–268) of
monoclonal antibody A20 (see next section). With the insertion of
Thr265 in AAV-6 relative to AAV-2, the local RMS difference of 2.7 Å
within VR-I is large and signiﬁcant when compared to the overall co-
ordinate error of 1.0 Å.
The second region where AAV-6 differs from its closest relatives is
within loop βGH, the ~220 residue segment running between β
strands G and H (Xie et al., 2002). Loop βGH contains 16 small β
strands, labeled βGH1 through 16, and can be divided into three
sub-loops (3a, 3b and 4). These sub-loops form many of the distinc-
tive features on the viral surface (Chapman and Agbandje-McKenna,
2006; Xie et al., 2002), exposing several of the variable regions. It is
sub-loop 3a that is most distinctive for AAV-6, in the GH2/3 β-
ribbon and turn that constitute VR-IV (Govindasamy et al., 2006).
13Q. Xie et al. / Virology 420 (2011) 10–19AAV-6 has its own turn conﬁguration. Loop 3a is one of the loops from
a pair of neighboring subunits that come together to form the three-
fold proximal spikes. In AAV-2, VR-IV forms a highly structured β-
ribbon of 22 residues with 10 inter-strand hydrogen bonds and a
tight 2-residue turn. In the other serotypes (3B, 6, 8 and 4), the ribbon
extends out only half as far with the strands connected by a meandering
turn that is different in each serotype. The average atomic B-factor for
these 22 residues is lowest in AAV-2 at 27 Å², modestly higher in AAV-4
and -8 (41 and 45 Å² respectively), and raised 30 Å² above average for
both forms of AAV-6 and -3B, an indication of some disorder. The need
to conform to different crystal packing contacts could be contributing to
higher B-factors. For example, in the rhombohedral form, 6 of the 20
NCS-related subunits form (distinct) contacts that could result in local
structural diversity which would be reﬂected in high B-factors for an
NCS averaged structure. However, the likely role of packing contacts
should not be over-stated as the rhombohedral and orthorhombic
forms have very different packing interactions yet fundamentally simi-
lar structures and B-factor distributions. With the exception of AAV-4,
which has a distinct structure, sequences in this 20-residue region are
very similar among the serotypes. The diversity of structure in a region
of conserved sequence suggests a loop built for ﬂexibility or adaptability
to different molecular interactions. VR-IV ﬁgures prominently in the 3-
fold proximal spikes. With the addition of the AAV-6 structure, we see
that AAV-2 is the outlierwith a longGH2/3β-ribbon forming aparticular-
ly pointed spike. Of the blunt-spike serotypes, two groups are emerging:
AAV-4's loop is folded over towards the three-fold axis, while the loops
of AAV-3B, -6 and -8 point away leading to the most distinctive differ-
ences in the surface topology (Fig. 2).
In the other seven variable regions (Govindasamy et al., 2006),
AAV-6 differs signiﬁcantly only from AAV-4. AAV-4 now emerges as
the outlier with more subtle differences between the other serotypes.
In fact, within most of the variable regions, the differences between
AAV-6 and AAV-4 exceed twice those between AAV-6 and other sero-
types. The structures have been determined with coordinateFig. 2. Surface topology. Panel (a): Themolecular surface of AAV-6 is shown,with one subunit h
-8 with variable region1 (VR-I) highlighted in cyan, and VR-IV highlighted in green. The positio
the surfaces are quite similar, with the exceptions of VR-I and VR-IV. At VR-IV there is some v
differences at VR-I are illustrated in Fig. 3.precisions of ~0.9 Å, so the expected error on distance measurements
is ~1.2 Å. In VR-I and VR-IV (highlighted in the previous paragraph),
the RMS Cα differences among non-AAV-4 serotypes are 1.6 to 3.4 Å,
i.e. statistically signiﬁcant. For the other seven variable regions, the
variation is 0.4 to 1.7 Å (Cα RMSD), i.e. commensurate with the
error. It is only when AAV-6 is compared to AAV-4 that the differ-
ences in these seven regions are signiﬁcant (Cα RMSDs of 1.7 to
4.7 Å). In summary, with the addition of AAV-6, it becomes clear
that the human AAV serotypes differ in backbone primarily at VR-I
and VR-IV, but that AAV-4 is an outlier differing in backbone at
seven other locations.
Antigenicity
Several monoclonal antibodies (mAbs) reacting with AAV capsids
have been described (Hermens et al., 1999;Weger et al., 1997;Wistuba
et al., 1995; Wobus et al., 2000). Antibody A20 binds both AAV-2 and
AAV-3. Antibodies C37B and C24 bind to AAV-2 capsids selectively,
while antibody D3 shows broad reactivity with different serotypes
from 1–6 and 8–9. Five antibodies highly speciﬁc for assembled
AAV1/6, AAV-4 or AAV-5 were described recently (Kuck et al., 2007).
Of all these antibodies, mAb A20 is the best characterized, recogniz-
ing a conformational epitope speciﬁc to assembled particles of AAV-2
(Wobus et al., 2000). With the AAV-6 structure, we can examine fea-
tures that distinguish it from AAV-2 and AAV-3 that are ~85% sequence
identical, but bound bymAbA20. Several sites have previously been im-
plicated as antigenic in AAV-2 (Fig. 3; Table S2). Residue Ala266, herein
designated “site 1”, was identiﬁed by scanning insertional mutagenesis
(Wu et al., 2000). Site 2 (Gln263, Ser264, Ser384, Gln385 and Val708) was
identiﬁed by individual site-directed mutations, as was site 3 (Glu548)
(Lochrie et al., 2006). By peptide scanning, Wobus et al. (2000) identi-
ﬁed three regions presumably containing antigenic residues: Arg566 to
Gln575 that we designate as site 4, His271 to Gly280 as site 5 and Phe370
to Leu378 as site 6. Sites 1, 2 and 5 come close together in the 3Dighlighted in yellow. Panels (b) through (f) show the boxed areas of AAV-6, -2, -3B, -4 and
ns of 3-fold and 5-fold axes of symmetry are denoted by “3” and “5” respectively. Overall,
ariation in the shape at the tip of the spike, AAV-4 being the most different. Detail of the
Fig. 3. Comparison of the structure and surface properties near the putative binding site of neutralizing antibody mAb A20. The surface structures of AAV-2 and AAV-3B (which are
recognized by mAb A20) are compared to AAV-6 (which is not). Panel (a) shows the molecular surface of AAV-6 capsid viewed parallel to a 5-fold axis. Panels (b)–(d) show detail of
the boxed region in (a). The direction of view is parallel to a ﬁve-fold. Surfaces are colored to highlight 6 sites that have been implicated as antigenic in AAV-2 through mutagenesis
or peptide scanning (numbered as in the text). The new structure of AAV-6 (panel d) has distinctive surface shape where several of the previously implicated regions come together
in the 3D structure (sites 1, 2 and 5). The site of an insertion at this location, unique to AAV-6, is labeled “Thr”. Panels (e)–(g) show the solvent accessible surface colored according
to the electrostatic potential from positive (blue) to negative (red). There are signiﬁcant differences between the serotypes over much of the surface, perhaps a reﬂection of the
selection of immune escape variants. The most distinctive of the differences between AAV-6 (g) and AAV-2/-3 (e/f) is between sites 2 and 4, where the A20-binding serotypes
are negatively charged, but AAV-6 is positively charged. These ﬁgures were prepared using PyMol and APBS (Baker et al., 2001; DeLano, 2002).
14 Q. Xie et al. / Virology 420 (2011) 10–19structures (Fig. 3). Here, there are structural differences between A20-
binding serotypes (AAV-2 and AAV-3) and non-binding AAV-6. Site 1
is surface-accessible in AAV-2 and -3, but buried in AAV-6. Within the
otherwise sequence-conserved site 2, there is an insertion (Thr265) in
AAV-6 and decreased accessibility of the loop compared to AAV-2 or
AAV-3. Site 5 is mostly buried underneath site 2 and likely impacts
antibody-binding only indirectly. Sites 4–6 have similar surface shape
in all serotypes, but the electrostatics of sites 3 and 4 are distinctive.
The surface potentials were calculated using a Poisson–Boltzmann con-
tinuum approach and reveal surprising overall diversity considering
the ~85% sequence identity between AAV-6, -2 and -3B (Fig. 3). A gluta-
mate in AAV-2 renders site 3 negative in contrast to neutral or slightlypositive potential in AAV-3B and -6 respectively (Fig. 3). An additional
basic residue renders site 4 positive in AAV-6 in contrast to the negative
potential in both AAV-2 and -3B.
In summary, A20 binding determinants should include surface
features conserved in AAV-2 and AAV-3B but different in non-
binding AAV-6. The surface shape differs where sites 1 and 2 come to-
gether, and the electrostatic charge at site 4 also correlates with A20-
binding. These sites are close enough to fall within a typical ~30 Å an-
tibody footprint and lie ~30 Å from AAV-2's HS attachment site, so it
is plausible that A20 could inhibit AAV-2 cell entry by steric conﬂict
with a receptor (Fig. 1c). High diversity in electrostatics over much
of the surface (considering the conserved sequence and structure)
15Q. Xie et al. / Virology 420 (2011) 10–19might be the result of the ease with which side chain charge could be
modulated in immune escape variants without impacting viral as-
sembly or other essential interactions.
Cell receptor binding
AAV-6 has been shown to bind to heparin (Halbert et al., 2001), an
analog of the HSPG primary cellular receptor for several human AAVs
(Summerford and Samulski, 1998). Like AAV-2, AAV-6 can be puriﬁed
using heparin sepharose columns, but the afﬁnity is weaker (Halbert et
al., 2001; Rabinowitz et al., 2002). Recently, the binding of heparin
to themost positively charged region of the AAV-2 surface has been visu-
alized directly through cryo-electron microscopy at 8 Å resolution
(O'Donnell et al., 2009). The binding site had been predicted from the
electrostatic potential, calculated from the AAV-2 crystal structure (Xie
et al., 2002) on the expectation that negatively charged HSPG would be
bound at a positively charged region of the viral surface. Intriguingly,
the AAV-2 arginines Arg585 and Arg588 that form the core of the binding
site, and have been implicated genetically in receptor-binding (Wu et al.,
2000), are unique to AAV-2 and not conserved in other heparin-binding
serotypes. For insights into heparin-binding differences, the electrostatic
potentials of AAV-6 and AAV-2 assembled capsids were compared fol-
lowing calculation by the Poisson–Boltzmann equation (Fig. 4).
In AAV-6, relative to AAV-2, the most positively charged region is
moved down the side of the spike towards the valley between neigh-
boring spikes. An additional region of positive charge is found around
the spike and closer to its tip (Fig. 4). Several sequence differences are
responsible for the changed electrostatics. In AAV-2, positive charge is
concentrated around Arg585 and Arg588, where the heparin is most
tightly bound in the cryo-EM structure (O'Donnell et al., 2009).
Arg585 and Arg588 are unique to AAV-2 among the 12 characterized
serotypes. Absent these two arginines, the corresponding exact loca-
tion in AAV-6 is less charged, but the surroundings remain predomi-
nantly positively charged (Fig. 4) with seven basic residues
contacting AAV-2's heparin when it is superimposed on the AAV-6
structure (Tables 2 and S3). Four of the seven residues are not con-
served between AAV-6 and AAV-2, and might compensate for the ab-
sence of AAV-2's Arg585 and Arg588. Close to the ﬂoor of the valley
between spikes, positive charge is increased with the substitution of
Lys531 and Arg576 for AAV-2's Glu530 and Gln575. Positive charge is
also gained near the tip of the spike on the side facing away from
the 3-fold axis (Fig. 4). This is due to the substitutions of AAV-6's
Lys459 for AAV-2's Ser458 and Lys493 for Ser492. Alone or inFig. 4. Surface charge near the heparin-binding sites on the spikes surrounding each 3-fold a
colored according to the surface electrostatic potential, ranging from−50 kT (dark red) to +
heparin from the cryo-electron microscopic study of an AAV-2 complex (O'Donnell et al., 20
to AAV-6 (K531) and three are unique to AAV-6 or -1 (K459, K493, R576) (Table 2). In panel
of AAV-2 is not positively charged in AAV-6. However, the most positively charged part of t
pears in contact with the heparin when its density is taken from AAV-2 and superimposed on
and K493.combination, these AAV-6 residues could compensate for the absence
of AAV-2's Arg585 and Arg588 though not in exactly the same location.
Some of these basic residues are unique to AAV-6 and its close rela-
tive, AAV-1. Lys459 and Lys493, which form the positive patch close to the
spike tip, are not conserved in any of the other serotypes. Lys493 is near
the distal end of loop 3b which is sandwiched between loop 3a and 4
from a neighboring subunit. The Lys459 that is ~6 Å from Lys493 comes
from loop 3a of the neighboring subunit. Lys493 is ~14 Å from the site
corresponding to AAV-2's Arg585 and Arg588 and the valley that is
more positively charged in AAV-6, with Arg576 and Lys531 is ~13 Å in
the opposite direction. Lys531, Arg576, Lys459 and Lys493 form a spiral of
positive potential rising from the valley towards the top of the spike
(Fig. 4). Although AAV-2, -3 and -6 all have positively charged regions
on the side of the spike, AAV-6's overlaps only partly with those of its
close relatives, and it is comprised of distinctly different basic amino
acids (Lerch et al., 2010; Xie et al., 2002). Sequence variability suggests
that other serotypes will be at least as different in this region.
In spite of the differences in how the positively charged regions
are constituted, it is plausible that the three serotypes bind HSPG in
analogous ways. This can be illustrated by superimposing the
experimentally-determined heparin location from AAV-2 onto the
surface of AAV-6 (Fig. 4) (O'Donnell et al., 2009). In AAV-2, 23 resi-
dues make direct contact with the heparin density (contoured at 4.7
error units), with 13 more having through-solvent access (O'Donnell
et al., 2009). In AAV-6, 28 residues have direct contact with the super-
imposed AAV-2 heparin density, while 10 have through-solvent ac-
cess (Table S3). Only a modest adjustment of AAV-2's heparin down
into the valley would be required to optimize interactions with a dif-
ferent cast of residues in AAV-6. Heparanoid polymers could still
wind around the virus between symmetry-related binding sites, as
proposed for AAV-2 (O'Donnell et al., 2009). Indeed, the trail of posi-
tive charge spiraling up from the valley ﬂoor towards Lys493 and
Lys459 high on the spike, suggests that the virus makes multiple inter-
actions with cell surface carbohydrate.
AAV-6 and AAV-1 differ at only six amino acids in their capsid se-
quences. However, the serotypes differ in receptor-binding, with
AAV-1 reported to lack heparin afﬁnity (Wu et al., 2006a). Qualitative
single-step elutions used in the earlier afﬁnity chromatography may
have exaggerated the effect (see below), but differences in heparin af-
ﬁnity are measurable for which only a subset of the six sites can be re-
sponsible. Phe129 is in the VP1-unique region of unknown structure,
present in only 13% of subunits. Asp418 and His642 are on the inner
surface of the capsid, far-removed from receptor-binding. Lys531,xis. AAV-6 (a, left) is compared to AAV-2 (b, right). The solvent accessible surfaces are
50 kT (dark blue). Superimposed on both AAV-2 (b) and AAV-6 (a), is the density for
09), contoured at 7.5σ. Labeled in panel (a) are 4 basic residues, one of which is unique
(b) are labeled R585 and R588 that are unique to AAV-2. The viral surface at R585/R588
he AAV-6 capsid is in the valley between 3-fold proximal spikes, a region that also ap-
AAV-6. Positive charge also extends part way around the spike in AAV-6 towards K459
16 Q. Xie et al. / Virology 420 (2011) 10–19Leu584 and Val598 are surface-exposed and near the proposed
receptor-binding site (Table S3). Neither Leu584 nor Val598 are con-
served and the residue types at these locations are not covariant
with heparin-binding. AAV-6's Lys531 is unique among all 12 serotypes,
with a glutamate at the corresponding location in AAV-1, -2,
-3B, -7, -8, -9, -10, and glycine, serine or alanine in the remaining sero-
types. Site-speciﬁc mutations at the six sites different in AAV-6 and -1
implicated only Lys531 as impacting heparin binding (Wu et al., 2006a).
The combination of structure and prior mutagenesis suggested to
us that AAV-6 receptor attachment is through a set of positively
charged residues that are not homologous to the heparin-binding
motif of AAV-2, but are in neighboring locations and serve an analo-
gous function. This hypothesis was tested with substitution muta-
tions at each position in the putative binding site where the
sequence differs between AAV-6 and -2. Mutants K531E, R576Q,
K493S and K459S all show reduced heparin-binding afﬁnity (Fig. 5).
All of these mutants are infectious in HeLa cells, so their phenotypes
appear to result from direct impact on binding interactions and not
collateral damage.
K531E is one of two weakly-binding mutants, consistent with its
earlier designation as an important determinant (Wu et al., 2006a).
Through the use of lower ionic strength (56 mM) buffers, weak
heparin-binding can be measured with elution at 140±10 mM
NaCl. This is, in contrast to an earlier designation as non-binding
frommeasurements in 123 mM buffers. To our knowledge, mutations
at the other sites have not previously been characterized and they all
have weakened binding, but to varying degrees. K459S has similarly
large impact upon binding as K531E, while R576Q and K493S have
more modest impact. It is important to note that there is not a single
amino acid that alone is critical, but there are several contributors to
binding of which K531 is among the more inﬂuential.
Thus, heparin-attachment in AAV-6 results from interactions with
several positively charged amino acids forming a binding site that
overlaps with, but differs somewhat from AAV-2's. The site in AAV-
6 is more similar to that of AAV-2 than AAV-3B (Lerch et al., 2010).
In AAV-3B, it was proposed that either the absence of AAV-2'sFig. 5. Heparin elution proﬁles for AAV-6 mutants. a) Representative PCR product gels for
fractions from a heparin afﬁnity column run with wild-type and 4 mutants, and eluted at
the salt concentrations indicated. pAAV6 DNAwas used to verify the location of the AAV-6
band. Intensities ofmutants varywith the unknown amount of PCR product loaded. b) The
relative intensities were ﬁttedwith Gaussian functions to determine the peak elution con-
centration. Data points show the mean of 3–5 replicates for each mutant.Glu499 (which neutralizes the conserved Arg447), or the presence of
Arg594, unique to AAV-3B, compensated for the absence of AAV-2's
Arg585 and Arg588. In AAV-6, the compensating residues are closer to
the binding site in AAV-2, lying on the side/base of the spike with di-
rect or solvent-mediated access to the heparin as it is seen in AAV-2
(O'Donnell et al., 2009). The one exception is Arg447 (AAV-3B/6)
which is on the side of the spike facing away from the 3-fold, and
out of contact with AAV-2's heparin density. In AAV-2 its charge is
neutralized by a salt-bridge partner (Glu499) unique to AAV-2, a sero-
type that binds heparin strongly. Thus, positive electrostatic potential
near Arg447 appears less important.
In conclusion, heparin binding in AAV-6 involves a variation on
the mode visualized in AAV-2 (O'Donnell et al., 2009). Intriguingly,
each serotype appears to be marshalling its own unique cast of
basic amino acids for heparin-binding. This suggests that there are
multiple ways that AAV can achieve adequate cell attachment. Evolu-
tionary diversity may be driven by the selective pressure to mutate
surface residues in response to immune surveillance. Tolerance of di-
versity at these locimay have allowed highly related serotypes to ac-
cumulate more sequence variability at this exposed functional site
than would otherwise be expected. The diversity is also encouraging
for gene therapy — there may be considerable freedom to engineer
desirable traits into the capsid without ablating cell attachment.
Materials and methods
Virus production, puriﬁcation, crystallization, data collection and processing
Wild type AAV-6 were produced from an infectious plasmid clone
(Rutledge et al., 1998) in human HeLa cells using a modiﬁcation of
high yield methods originally developed for AAV-2 (Xie et al.,
2004). Details of the production, puriﬁcation, crystallization and
data collection/processing were reported previously (Xie et al.,
2008). In summary, several data sets were collected from pre-frozen
crystals at F1 beamline at Cornell High Energy Synchrotron Source
(CHESS) of which the best two are used here. One was processed
with a primitive rhombohedral R3 unit-cell with parameters
a=b=258.4 Å, c=613.0 Å in the hexagonal setting. The other crys-
tal was processed in a primitive orthorhombic unit-cell with parame-
ters a=354.8, b=363.9, c=371.9 Å. The program suite HKL2000
was used for data processing (Otwinowski and Minor, 1997).
Structure determination and reﬁnement
Crystal structures of AAV-6were determined for two crystal forms.
Due to variability in the diffraction from individual crystals, structures
were determined from the datasets of individual crystals without
merging. The best datasets were 30–40% complete, not uncommon
in virus crystallography, where the datasets are ~100-fold larger
than for typical proteins, and data collection is limited by radiation
damage even at cryogenic temperatures. Structure determination
continued with these partial datasets, encouraged by precedents
where viral symmetry had compensated for even sparser data (Badger
et al., 1988). It was not immediately clear which 3 Å data set would
yield the better structure. The rhombohedral datawere of higher quality
(Rmerge=0.08; Table 1), theparticle positionwas pre-determined by the
space group, and they ultimately yielded a higher quality phase
extension.
Virus orientations were determined for both crystals through the
self-rotation function, locked according to the icosahedral symmetry,
using the program GLRF (Tong and Rossmann, 1997). There is only
one particle in the primitive rhombohedral cell, so it can be posi-
tioned arbitrarily on the crystallographic 3-fold axis. There are 4 par-
ticles in the orthorhombic cell (1 per asymmetric unit). The virus
position was determined by R-factor search over the asymmetric
unit, starting at 12 Å resolution using the program Phenix (Adams
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7.5–3.0 Å resolution using the program CNS (Brünger et al., 1998).
Phases were determined for the rhombohedral form at low 8 Å
resolution from atomic model AAV-2, then extended by 20-fold
non-crystallographic symmetry averaging using RAVE and the CCP4
program suite (Collaborative Computational Project Number 4,
1994). The model was built using the program ‘O’ (Jones et al.,
1991), followed by alternate cycles of reﬁnement in CNS and re-
building. Models were built into updated (2Fo−Fρav, φρav) averaged
maps, where the subscript ρav indicates (model-free) calculation by
back-transform from the symmetry-averaged map. The ﬁnal round
of model building was performed using COOT (Emsley and Cowtan,
2004) with reﬁnement completed in Phenix (Adams et al., 2010).
To monitor reﬁnement of the rhombohedral form, a non-biased
test set of 985 reﬂections were set aside using Rfree2005 (Fabiola et
al., 2006). This method eliminates bias from non-crystallographic
symmetry by selecting the test reﬂections as thin shells in resolution.
Beyond the usual precautions, it then omits from both test andworking
sets, the reﬂections in neighboring resolution shells that would allow
cross-talk through the interference function. From the 83,983 scaled re-
ﬂections between 40 and 3.0 Å, 985 test reﬂections were selected, and
15,150 neighbors were omitted, leaving a working set of 68,833 reﬂec-
tions. The reported Rfree of many other virus structures have not been
calculated with the precautions needed to eliminate bias, and are little
different from Rwork. The higher values of Rfree here are more in line
with the usual properties of the statistic.
Even though of modest resolution, the availability of 20-fold NCS
for the rhombohedral form led to reliable electron density into
which the protein sequence could be ﬁt readily (Fig. 1). Tests were
performed to check that the averaging with 20-fold NCS and 30%
completeness were sufﬁcient to remove bias towards the initial
AAV-2 phasing model. In separate repetitions of the phase reﬁnement
and extension, three regions were omitted from the phasing model:
AAV-2 VP1 450–463, 465–476 and 545–558, where differences be-
tween AAV-2 and AAV-6 were expected. The averaged omit maps
showed good density that was essentially unchanged from the con-
ventionally calculated non-omit averaged maps. Furthermore, clear
density was recovered for a lysine at the site of the S459K sequence
difference between AAV-2 and AAV-6.
Phases for the orthorhombic form were determined from both the
AAV-2 and rhombohedral AAV-6 atomic models. Upon iterative NCS
phase reﬁnement to 3.5 Å resolution, both starting points yielded
similar statistics, and the latter was extended to 3.0 Å using 60-fold
NCS averaging in RAVE and the CCP4 program suite. Concerned about
the potential formodel bias, NCS phase reﬁnements for the orthorhom-
bic form were compared where the initial phasing model was either a
complete rhombohedral model or one from which residues 459, 493,
531, 576 and 580–95 were omitted. Following NCS phase reﬁnement,
there were no perceptible differences anywhere in the omit and non-
omit maps, conﬁrming the power of the 60-fold NCS to yield unbiased
maps which were of somewhat higher quality than the 20-fold aver-
aged rhombohedral maps.
The orthorhombic model was ﬁt to the NCS-averaged omit map
manually and with real-space torsion angle simulated annealing re-
ﬁnement using a new implementation of RSRef as an extension to
CNS 1.2 (Brünger et al., 1998; Chapman, 1995). This was followed
by reciprocal space reﬁnement at 3.0 Å against a maximum likelihood
target using Phenix 1.7 (Adams et al., 2010).Electrostatics calculations
The program APBS was used to calculate the potentials (Baker et
al., 2001). First, the potentials were estimated over a coarse grid for
assembled capsids, and then reﬁned on a ﬁne grid near the icosahe-
dral 3-fold axis.Preparation of AAV-6 mutants
Mutants were designed to characterize regions implicated by the
structure in heparin-binding. The starting point was the pAAV6 infec-
tious clone, a gift from David Russell, comprising AAV6 rep and cap
ﬂanked by AAV6 inverted terminal repeats (ITRs). For mutagenesis,
to avoid complications from the ITRs, cap was excised (pAAV6 nt
1889–4614) using endogenous ﬂanking SacI sites, and inserted into
the pET-41a(+) cloning vector (Novagen), using a homologous SacI
site within the multiple cloning site (MCS) to yield the plasmid
pET41a/pAAV6-SacI. The following mutations were introduced into
this plasmid by mutagenic PCR using the QuikChange II XL Site-
Directed Mutagenesis Kit (Stratagene), and primers listed in Table
S4: K531E, R576Q, K459S, and K493S. Mutant plasmids were digested
with SacI and the cap region extracted and ligated back into the SacI-
digested parental pAAV6 plasmid to yield infectious mutant clones.
Following ampliﬁcation in E. coli, infectious mutant viruses were pro-
duced by HeLa transfection in the presence of Adenovirus helper, and
then puriﬁed by at least one cesium gradient ultracentrifugation (Xie
et al., 2008). Constructs were conﬁrmed by sequencing of the cap re-
gion of the plasmid, and of the puriﬁed virion genomes.Heparin afﬁnity of mutant viruses
Heparin binding afﬁnity was measured using 1 mL HiTrap Heparin
HP columns (GE HealthCare) that were pre-washed with 10 mL 5 M
NaCl followed by 10 mL loading buffer. Virus samples of 0.05 to
0.25 μg were diluted in 5 mL loading buffer (25 mM Na Hepes,
31.25 mM NaCl, pH=7.2–7.4). To better resolve weakly-binding
virus particles, buffers used for the afﬁnity chromatography were at
lower ionic strength (56 mM) than in earlier work (123 mM) (Wu
et al., 2006a). After sample loading, columns were washed with
25 mL loading buffer. Bound virus was eluted with a NaCl gradient
consisting of 5 mL steps in increments of 100 mM from 100 mM to
1 M. Fractions, ﬂow-through (FT) and wash (W) were assayed for
virus using PCR in the following way. Fraction aliquots of 2–8 μL
were made up to 10 μL by mixing with DNA extraction buffer (2 μL
proteinase K and 1 μL Tween-20 in 1 mL TE buffer (10 mM Tris–HCl,
1 mM EDTA, pH 7.5). Capsid digestion proceeded at 56 °C for 1.5 h
and was quenched for 1 h at 90 °C to denature proteinase K. PCR
was performed using the DreamTaq Green Master Mix (Fermentas)
(Mitchell et al., 2006). Ampliﬁed fragments were separated on 1.5%
agarose gels which were scanned using the FluorChem 5500 (Alpha
Innotech Inc.). The centroid elution concentrations were obtained
by non-linear least-squares ﬁtting of Gaussian functions (SigmaPlot)
to the integrated relative band densities for the PCR products of the
heparin column fractions. Results are the average of 3 or 4 elution
proﬁles for each mutant.Acknowledgments
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